Clinical Trial: Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy
Brief Summary: This study will investigate the effects of rosiglitazone, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. The primary purpose of the study is to determine whether treatment with an insulin-sensitizing medication will improve the heart's ability to metabolize glucose (sugar).
Detailed Summary: Nondiabetic patients with nonischemic cardiomyopathy who are insulin-resistance or insulin-sensitive based on a fasting homeostasis model assessment (HOMA) value are eligible for the trial. At baseline, a 6-minute walk test is performed, followed by assessment of coronary flow reserve with ammonia-PET imaging before/after adenosine infusion. Subjects are then given an oral glucose load (75g), followed by PET imaging with F-18-fluoro-2-deoxyglucose (FDG). Subjects then begin taking rosiglitazone 4 mg qd x 12 weeks, after which the 6-minute walk test & PET imaging is repeated.
Sponsor: Stanford University
Current Primary Outcome:
- Myocardial glucose uptake (intrasubject before/after rosiglitazone)
- Myocardial glucose uptake (between insulin-resistant & insulin-sensitive groups)
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Coronary flow-reserve
- 6-minute walk time
Original Secondary Outcome: Same as current
Information By: Stanford University
Dates:
Date Received: April 25, 2007
Date Started: March 2007
Date Completion:
Last Updated: May 12, 2014
Last Verified: May 2014
